Monitor PSA Kinetics

Abstract

PSA is a follow-up signal, not an emergency branch. Current AUA/SUO and EAU guidance supports confirming a newly elevated/borderline PSA under standardized conditions before biomarkers, MRI, or biopsy; PSA velocity should not be used alone. If the repeat stays near/above 3 ug/L or risk markers are concerning, use free/total PSA, DRE, risk calculator, prostate-volume/PSA-density, and urology/MRI rather than jumping straight to biopsy.

urology · psa · prostate · cancer-screening · psa-velocity · mri

PSA Kinetics & Prostate Risk

Summary

The cloud doc records PSA 1.3 -> 1.5 -> 2.0 -> 2.85 ug/L across 2015-2026, with no urinary symptoms documented. This is close enough to work-up thresholds to repeat deliberately, but not a stand-alone cancer alarm.

AUA/SUO 2023 plus the 2026 amendment says repeat a newly elevated PSA before biomarkers, imaging, or biopsy, and do not use PSA velocity alone. EAU is more concrete for asymptomatic men: if PSA is 3-10 ng/mL and DRE is not suspicious, repeat after about 4 weeks; if it normalizes, resume interval follow-up.

Standardized repeat

Order at Biomed: PSA Total ($10, 1 day). If this is meant to resolve the branch rather than just trend it, add Free PSA / PSA Free ($15, 1 day) at the same draw so percent-free PSA can be interpreted.

Before the draw:

Use the same lab/assay when practical.
Avoid ejaculation, vigorous cycling, prostate manipulation, and testing during UTI/prostatitis/fever.
Do not treat one borderline result as a biopsy decision; biologic and lab variation are large enough that repeat testing changes management.

Escalation table

Repeat result / context	Meaning	Practical next step
PSA falls clearly toward prior baseline	Transient fluctuation more likely	Return to trend monitoring; avoid over-reading velocity.
PSA remains around 2.5-3.0	Still borderline, not diagnostic	Calculate percent-free PSA if available; consider clinician DRE and risk calculator.
PSA rises above ~3.0 or keeps rising on standardized repeats	Work-up branch persists	Urology review is reasonable; add DRE, percent-free PSA, and prostate-volume context.
Low percent-free PSA, abnormal DRE, strong family/genetic risk, or concerning risk calculator	Higher risk of clinically significant cancer	Urology-led mpMRI before biopsy is the modern pathway when available.
MRI PI-RADS 3-5 or high PSA density	Lesion/volume-adjusted risk becomes material	Urology decides targeted/systematic biopsy; do not self-manage from PSA alone.

Interpretation boundaries

PSA velocity: useful as background trend, but not a stand-alone escalation rule. AUA/SUO explicitly says not to use velocity alone for biomarkers, imaging, or biopsy; Vickers/ERSPC repeat-biopsy data found weak added discrimination.
Age-specific ranges: treat them as rough context, not a hard reassurance rule. At age 51, the issue is that PSA is now near action thresholds and has risen, not that it crosses a universal cancer cutoff.
Percent-free PSA: helps risk stratification when total PSA is borderline, but it is context, not a yes/no cancer test.
PSA density: requires prostate volume from ultrasound or MRI; >0.15 ng/mL/cc is a commonly used concern threshold, while EAU now discusses higher thresholds such as 0.20 when MRI is negative.
DRE: not a sole screening tool, but useful alongside PSA when the branch remains active.

References

AUA/SUO Early Detection Guideline Part I, 2023: PSA first, repeat newly elevated PSA, no PSA-velocity-only escalation, DRE/risk-calculator context. PMID: 37096582.
AUA/SUO Part II and 2026 amendment: biomarkers/MRI/biopsy are for risk-stratified decisions focused on Grade Group 2+ disease. PMIDs: 37096575, 41744286.
EAU Prostate Cancer Diagnostic Evaluation: repeat PSA under standardized conditions before further work-up in asymptomatic PSA 3-10 ng/mL with non-suspicious DRE. https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
PSA velocity evidence: limited added value beyond PSA alone in ERSPC repeat-biopsy analysis. PMID: 20643434.
Biomed Phnom Penh tariff checked 2026-05-03: PSA Total $10; Free PSA / PSA Free $15; both serum, 1-day turnaround.